OLALEKAN OLATUNDE FADEBI

Mr. OLALEKAN OLATUNDE FADEBI

Nuclear Medicine, Nuclear Medicine Research Infrastructure (NuMeRI), Pretoria, Gauteng, South Africa
+1
orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2025 in Non-Coding RNA
Verified
Journal Article
Open access
PDF file
OFOLALEKAN OLATUNDE FADEBI
OLALEKAN OLATUNDE FADEBI
TMThabiso Victor Miya
Thabiso Victor Miya
RKRichard Khanyile
Richard Khanyile
ZDZodwa Dlamini
Zodwa Dlamini
RMRahaba Marima
Rahaba Marima
Breast cancer is one of the leading causes of mortality among women, primarily due to its complex molecular landscape and heterogeneous nature. The tendency of breast cancer patients to develop metastases poses significant challenges in clinical management. Notably, mutations in the breast cancer gene 1 (BRCA1) significantly elevate breast cancer risk. The current research endeavors employ diverse molecular approaches, including RNA, DNA, and protein studies, to explore avenues for the early diagnosis and treatment of breast cancer. Recent attention has shifted towards long non-coding RNAs (lncRNAs) as promising diagnostic, prognostic, and therapeutic targets in the multifaceted progression of breast cancer. Among these, long intergenic non-coding RNAs (lincRNAs), a specific class of lncRNAs, play critical roles in regulating various aspects of tumorigenesis, including cell proliferation, apoptosis, epigenetic modulation, tumor invasion, and metastasis. Their distinctive expression patterns in cellular and tissue contexts underscore their importance in breast cancer development and progression. Harnessing lincRNAs’ sensitivity and precision as diagnostic, therapeutic, and prognostic markers holds significant promise for the clinical management of breast cancer. However, the potential of lincRNAs remains relatively underexplored, particularly in the context of BRCA1-mutated breast cancer and other clinicopathological parameters such as receptor status and patient survival. Consequently, there is an urgent need for comprehensive investigations into novel diagnostic and prognostic breast cancer biomarkers. This review examines the roles of lincRNAs associated with BRCA1 in the landscape of breast cancer, highlighting the potential avenues for future research and clinical applications.

4 June 2024
Verified
Book Chapter
Closed access
PDF file
RMRahaba Marima
Rahaba Marima
OFOLALEKAN OLATUNDE FADEBI
OLALEKAN OLATUNDE FADEBI
BMBenny Mosoane
Benny Mosoane
ABAfra Basera
Afra Basera
LGLinomtha Gabada
Linomtha Gabada
ZDZodwa Dlamini
Zodwa Dlamini

1 June 2026 in Epigenomes
Verified
Journal Article
Open access
PDF file
OFOLALEKAN OLATUNDE FADEBI
OLALEKAN OLATUNDE FADEBI
BABabatunde Adebola Alabi
Babatunde Adebola Alabi
RKRichard Khanyile
Richard Khanyile
ZDZodwa Dlamini
Zodwa Dlamini
RMRahaba Marima
Rahaba Marima
Background: Triple-negative breast cancer (TNBC) remains a clinical challenge due to its aggressive nature and the frequent emergence of therapeutic resistance. While the role of protein-coding genes in DNA repair is well-documented, the regulatory contributions of the non-coding genome, specifically long intergenic non-coding RNAs (lincRNAs), remain largely undefined. Objectives: In this study, we characterize the biological significance of LincRNA-BC7, a novel transcript identified within the breast cancer field effect. Methods: Through a combined in silico and in vitro approach, we investigated the transcriptional dynamics of the LincRNA-BC7/miR-663a/BRCA1 axis in response to the PARP inhibitor, Olaparib. Results: Our results demonstrate that Olaparib induces selective cytotoxicity in BRCA1-deficient MDA-MB-231 cells while sparing non-cancerous HEK293 cells, a response accompanied by a significant downregulation of LincRNA-BC7 and a reciprocal upregulation of BRCA1. Bioinformatics analysis through BLASTN, miRBase, and KEGG revealed that LincRNA-BC7 contains highly complementary binding sites for miR-663a, suggesting it functions as a competing endogenous RNA (ceRNA) or “molecular sponge.” Conclusions: By sequestering miR-663a, LincRNA-BC7 appears to modulate the expression of critical signaling nodes within the PI3K-AKT and TP53 pathways, thereby influencing cellular sensitivity to DNA-damaging agents. These findings suggest that LincRNA-BC7 is a key determinant of the aggressive TNBC phenotype and the response to PARP inhibition. Our study establishes the LincRNA-BC7/miR-663a axis as a novel biomarker for precision risk stratification and a promising therapeutic target to enhance treatment outcomes in BRCA1-associated breast cancers.

4 June 2024
Verified
Book Chapter
Closed access
PDF file
TLThifhelimbilu Emmanuel (E) Luvhengo
Thifhelimbilu Emmanuel (E) Luvhengo
TMThabiso Victor Miya
Thabiso Victor Miya
ABAfra Basera
Afra Basera
OFOLALEKAN OLATUNDE FADEBI
OLALEKAN OLATUNDE FADEBI
RAVI MEHROTRARAVI MEHROTRA
RAVI MEHROTRA
ZDZodwa Dlamini
Zodwa Dlamini

13 September 2024
Verified
Book Chapter
Closed access
PDF file
RMRahaba Marima
Rahaba Marima
ABAfra Basera
Afra Basera
PDPatrick T. Dumakude
Patrick T. Dumakude
OFOLALEKAN OLATUNDE FADEBI
OLALEKAN OLATUNDE FADEBI
LGLinomtha Gabada
Linomtha Gabada
ZDZodwa Dlamini
Zodwa Dlamini
Gut microbiome biomarkers hold great potential in early cancer diagnosis and in prognosis. Advances in translational research have demonstrated that the gut microbiome might be utilized as a less invasive diagnostic tool. Not only are gut microbes abundant, they are also unique. Emerging reports demonstrate that humans carry 80–90% unique gut microbiome signatures, compared to the inter-human genome similarity of 99.9%. The association between the gut microbiome and cancer has been studied, particularly in colorectal cancer (CRC). Nevertheless, a significant research gap still exists, which includes the translational application of the gut microbiome in early cancer diagnosis and prognosis from in vitro and animal models to humans. The intricate relationship between various gut microbes and between the host and external factors complicates the gut microbiome-CRC association. Despite these challenges, advances in sequencing technologies and computational biology are shifting this paradigm. Alterations in the gut microbiome in CRC have been concretely documented. This chapter discusses the gut microbiome biomarkers as frontiers in CRC diagnosis and prognosis. <!----> <!----> <!----> <!---->